The HDAC8 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung adenocarcinoma epithelial cell line. This product provides a loss-of-function model for HDAC8 through targeted gene disruption, yielding a heterogeneous pool of cells that avoids clonal artifacts and maintains population-level relevance. It is designed for rigorous studies of HDAC8-mediated mechanisms in transcriptional regulation, chromatin biology, and cancer pathogenesis.
The A-549 host is a hypotriploid epithelial cell line established from a 58-year-old Caucasian male with lung carcinoma. Widely employed in non-small cell lung cancer research, A-549 cells retain characteristic genetic alterations and exhibit robust adherent growth. This well-characterized model provides a physiologically relevant context for investigating the impact of HDAC8 ablation on lung adenocarcinoma cell behavior, including proliferation, apoptosis, and drug response.
HDAC8, a class I histone deacetylase, catalyzes removal of acetyl groups from lysines on histones H3/H4 and non-histone targets such as p53, SMC3, cortactin, and ERR??. Its activity is regulated by PKA phosphorylation and through interactions with SMRT/N-CoR corepressor complexes and cohesin components SMC3 and RAD21. By deacetylating these substrates, HDAC8 modulates chromatin structure, gene expression, cell cycle progression, and apoptosis. Knockout in A-549 cells abolishes deacetylation, leading to hyperacetylation of histones and non-histone proteins, which disrupts key signaling cascades. For example, hyperacetylated p53 may enhance transactivation of pro-apoptotic genes, while aberrant SMC3 acetylation impairs cohesin function, altering Notch1-HES1 signaling. Additionally, dysregulation of p21 and BCL2 expression affects cell cycle and survival, collectively contributing to impaired proliferation and increased apoptosis.
In the context of lung adenocarcinoma, HDAC8 has been associated with oncogenic transcriptional programs and resistance to chemotherapy. This knockout model enables dissection of HDAC8-dependent epigenetic alterations, cohesin dynamics, and Notch pathway modulation in a relevant cancer setting. It is instrumental for examining the cellular response to HDAC inhibitors and for identifying potential synthetic lethal interactions. Beyond lung cancer, HDAC8 is implicated in acute myeloid leukemia, neuroblastoma, and the cohesinopathy Cornelia de Lange syndrome, underscoring the model’s broader utility for studying cohesin-related pathologies.
These polyclonal knockout cells support a range of applications, including epigenetic cancer research, HDAC inhibitor drug screening, and investigation of cohesin biology. Representative assays include Western blotting for acetylated histones H3/H4 and targets like p53 or SMC3, RT-qPCR for gene expression profiling (e.g., p21, BCL2, Notch1), ChIP-qPCR to assess promoter histone acetylation, cell proliferation (MTT/BrdU) and apoptosis (Annexin V/PI) assays, Transwell migration, and flow cytometry for cell cycle analysis. The polyclonal nature ensures that observed phenotypes reflect population-level effects. For further technical specifications or ordering, please contact Ascent Research.
